Published in BMC Cardiovasc Disord on December 12, 2003
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care (1997) 49.11
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature (1987) 4.54
Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation (1999) 3.08
Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest (1990) 2.16
Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA (1986) 2.08
Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation (1986) 2.06
Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation (1996) 2.02
Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A (1987) 1.61
Association of the G-2548A polymorphism in the 5' region of the LEP gene with overweight. Ann Hum Genet (2000) 1.53
Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem (2000) 1.52
Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol (2000) 1.32
Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis (1990) 1.24
Sequence variants in the 5' flanking region of the leptin gene are associated with obesity in women. Ann Hum Genet (1999) 1.22
Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet (1991) 1.20
Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb (1992) 1.17
Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis (1999) 1.15
Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci (2001) 1.13
A comparison between BMI and Conicity index on predicting coronary heart disease: the Framingham Heart Study. Ann Epidemiol (2000) 1.13
Risk stratification of obesity as a coronary risk factor. Am J Cardiol (2002) 1.09
Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun (1993) 1.00
The economic cost of obesity: the French situation. Int J Obes Relat Metab Disord (1995) 0.97
Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol (2003) 0.96
Contribution of apolipoprotein(a) size, pentanucleotide TTTTA repeat and C/T(+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians. Atherosclerosis (1999) 0.87
LEPR gene polymorphisms: associations with overweight, fat mass and response to diet in women. Eur J Clin Invest (2001) 0.86
Clinical significance of exercise-induced silent myocardial ischemia in patients with coronary artery disease. J Am Coll Cardiol (1987) 0.85
Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. Int J Cardiol (2003) 0.84
Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol (1999) 0.83
Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med (2002) 0.82
Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease. J Cardiovasc Risk (2001) 0.80
Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin Chim Acta (1993) 0.79
Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site. Biol Chem (2002) 0.79
Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. J Cardiovasc Risk (1998) 0.79
Metabolic and anthropometric determinants of serum Lp(a) concentrations and Apo(a) polymorphism in a healthy Arab population. Int J Obes Relat Metab Disord (1999) 0.78
Lipoprotein(a) in android obesity and NIDDM. Diabetes Care (1997) 0.78
Apo(a) isoforms do not predict risk for coronary heart disease in a Gulf Arab population. Ann Clin Biochem (2000) 0.78
Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. Arterioscler Thromb Vasc Biol (1998) 0.78
Serum lipoprotein Lp(a) in obesity. Diabetes Res (1992) 0.77
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol (2005) 3.21
Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine (2011) 2.18
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res (2010) 2.09
Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation (2004) 1.92
Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J (2006) 1.64
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res (2010) 1.54
Raised plasma nerve growth factor levels associated with early-stage romantic love. Psychoneuroendocrinology (2005) 1.51
Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem (2006) 1.44
QT interval duration in apparently healthy men is associated with depression-related personality trait neuroticism. J Psychosom Res (2006) 1.42
Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol (2005) 1.30
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium (2006) 1.27
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens (2005) 1.26
Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int (2009) 1.21
Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. Neurosci Lett (2005) 1.19
Prevalence of CKD in northeastern Italy: results of the INCIPE study and comparison with NHANES. Clin J Am Soc Nephrol (2010) 1.15
Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care (2002) 1.08
Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem (2011) 1.07
TGFbeta1 induces epithelial-mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture. Int J Exp Pathol (2006) 1.06
Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis (2004) 1.05
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels (2007) 1.05
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism (2009) 1.04
Preliminary evidence of a genetic association between chromosome 9p21.3 and human longevity. Rejuvenation Res (2010) 1.01
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis (2005) 1.01
Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. J Bone Miner Res (2012) 0.97
Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: hope for lower risks with alternative therapies. Curr Vasc Pharmacol (2011) 0.96
Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol (2010) 0.96
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res (2007) 0.95
Apolipoprotein(a) null phenotype is related to a delayed age at onset of Alzheimer's disease. Neurosci Lett (2004) 0.95
Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens (2010) 0.93
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. Diabetes Technol Ther (2009) 0.93
Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation (2013) 0.93
The origin of nephrocalcinosis, Randall's plaque and renal stones: a cell biology viewpoint. Arch Ital Urol Androl (2009) 0.92
Association analysis of the functional Ala111Glu polymorphism of the glyoxalase I gene in panic disorder. Neurosci Lett (2005) 0.91
A novel Val734Ile variant in the ABCC9 gene associated with myocardial infarction. Clin Chim Acta (2006) 0.90
Crystals, Randall's plaques and renal stones: do bone and atherosclerosis teach us something? J Nephrol (2004) 0.90
High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc (2006) 0.90
Relationship between platelet serotonin content and rejections of unfair offers in the ultimatum game. Neurosci Lett (2008) 0.90
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol (2012) 0.89
Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract (2005) 0.89
Perforin, Granzyme B, and fas ligand for molecular diagnosis of acute renal-allograft rejection: analyses on serial biopsies suggest methodological issues. Transplantation (2006) 0.89
An unusual association of contralateral congenital small kidney, reduced renal function and hyperparathyroidism in sponge kidney patients: on the track of the molecular basis. Nephrol Dial Transplant (2005) 0.88
Increased plasma aldosterone in patients with clinical depression. Arch Med Res (2005) 0.88
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. Heart Vessels (2009) 0.88
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med (2009) 0.88
The regenerative potential of the kidney: what can we learn from developmental biology? Stem Cell Rev (2010) 0.87
Brain-derived neurotrophic factor and the metabolic syndrome: more than just a hypothesis. Med Hypotheses (2006) 0.87
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin (2009) 0.87
Identification of GDNF gene sequence variations in patients with medullary sponge kidney disease. Clin J Am Soc Nephrol (2010) 0.86
Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens (2013) 0.86
Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int (2003) 0.86
Genetic loading on human loving styles. Neuro Endocrinol Lett (2007) 0.86
Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther (2013) 0.85
Association between platelet endothelial cellular adhesion molecule-1 polymorphisms and atherosclerosis: results of a study on patients from northern Italy. Rejuvenation Res (2010) 0.85
Sepsis and AKI in ICU Patients: The Role of Plasma Biomarkers. Crit Care Res Pract (2012) 0.85
Genes involved in TGF beta1-driven epithelial-mesenchymal transition of renal epithelial cells are topologically related in the human interactome map. BMC Genomics (2007) 0.85
Coronary spasm and acute myocardial infarction due to a mutation (V734I) in the nucleotide binding domain 1 of ABCC9. Int J Cardiol (2013) 0.85
Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis. J Nephrol (2003) 0.84
Dent's disease and prevalence of renal stones in dialysis patients in Northeastern Italy. J Hum Genet (2005) 0.84
Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism. Cardiovasc Diabetol (2002) 0.84
Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium (2007) 0.84
A W148R mutation in the human FOXD4 gene segregating with dilated cardiomyopathy, obsessive-compulsive disorder, and suicidality. Int J Mol Med (2007) 0.84
Alterations of circulating endogenous secretory RAGE and S100A9 levels indicating dysfunction of the AGE-RAGE axis in autism. Neurosci Lett (2006) 0.84
ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications. J Nephrol (2010) 0.84
Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index. Diabetes Care (2013) 0.83
Adiponectin expression in subcutaneous adipose tissue is reduced in women with cellulite. Int J Dermatol (2011) 0.83
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol (2010) 0.83
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium (2007) 0.83
Decorin transfection in human mesangial cells downregulates genes playing a role in the progression of fibrosis. J Clin Lab Anal (2002) 0.83
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res (2006) 0.83
Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. ScientificWorldJournal (2013) 0.83
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J (2010) 0.83